Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.

Ronald van VollenhovenTsutomu TakeuchiAileen L PanganAlan FriedmanMohamed-Eslam F MohamedSu ChenMaureen RischmuellerRicardo Blanco-AlonsoRicardo M XavierVibeke Strand

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2020)

Our findings indicate that patients receiving either dose of upadacitinib monotherapy experienced significant improvements in clinical, radiographic, and PROs compared to patients receiving MTX.

Keyphrases

double blind
placebo controlled
open label
clinical trial
rheumatoid arthritis
phase iii
combination therapy
phase ii
study protocol
hiv infected
high dose
disease activity
systemic lupus erythematosus
interstitial lung disease
ankylosing spondylitis
randomized controlled trial
low dose
systemic sclerosis